4.03

2.88% -0.09

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Discussions Forecast

Kyverna Therapeutics Inc stock is traded at $4.03, with a volume of 78,435. It is down -2.88% in the last 24 hours and down -23.05% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Previous Close:

$4.12

Open:

$4.17

24h Volume:

78,435

Relative Volume:

0.24

Market Cap:

$180.03M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-16.64%

1M Performance:

-23.05%

6M Performance:

-70.79%

1Y Performance:

+0.00%

1-Day Range:

$3.97

$4.17

1-Week Range:

$3.94

$4.85

52-Week Range:

$3.94

$30.60

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(510) 626-8331

Address

5980 HORTON STREET, EMERYVILLE

Employee

119

Twitter

Next Earnings Date

Latest SEC Filings

KYTX's Discussions on Twitter

Compare KYTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYTX	4.03	180.03M	0	0	0	0.00
VRTX	447.05	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.71	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.15	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.84	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.92	24.49B	3.30B	-501.07M	1.03B	11.54

Kyverna Therapeutics Inc Stock (KYTX) Latest News

02:13 AM

Kyverna stock plunges 28% amid data update on lead drug - MSN

02:13 AM

Nov 20, 2024

HC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $6.00 - MarketBeat

Nov 20, 2024

Kyverna stock maintains Neutral rating as analyst revises outlook amid higher costs - Investing.com UK

Nov 20, 2024

Nov 18, 2024

What is Leerink Partnrs’ Forecast for KYTX FY2024 Earnings? - Defense World

Nov 18, 2024

Nov 17, 2024

institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop - Yahoo Finance

Nov 17, 2024

Wells Fargo & Company Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $24.00 - Defense World

Nov 17, 2024

Nov 14, 2024

Kyverna's CAR T-Cell Therapy Shows Promising Results in Lupus Nephritis Treatment | KYTX Stock News - StockTitan

Nov 14, 2024

Creative Planning Acquires Shares of 11,028 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World

Nov 14, 2024

Nov 13, 2024

Kyverna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - StreetInsider.com

Nov 13, 2024

Nov 09, 2024

(KYTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 09, 2024

Nov 08, 2024

Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $28.71 - Defense World

Nov 08, 2024

Nov 05, 2024

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Nov 05, 2024

Oct 30, 2024

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat

Oct 30, 2024

Oct 29, 2024

(KYTX) Trading Report - Stock Traders Daily

Oct 29, 2024

Oct 27, 2024

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat

Oct 27, 2024

Oct 24, 2024

Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com

Oct 24, 2024

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire

Oct 22, 2024

Oct 21, 2024

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com

Oct 21, 2024

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors | KYTX Stock News - StockTitan

Oct 21, 2024

Oct 19, 2024

Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey

Oct 19, 2024

Oct 18, 2024

(KYTX) Technical Data - Stock Traders Daily

Oct 18, 2024

Oct 17, 2024

500: Something went wrong - Investing.com

Oct 17, 2024

JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK

Oct 17, 2024

7 Best Nano Cap Stocks To Invest In - Insider Monkey

Oct 17, 2024

Oct 15, 2024

The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News

Oct 15, 2024

Oct 14, 2024